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Background: Standard methods to prevent chemotherapy-induced early menopause in young, breast cancer
patients are unavailable to date. Preclinical data has suggested that luteinising hormone-releasing hormone (LH-RH)
analogs given during treatment can decrease the gonado-toxicity induced by chemotherapy. This phase II study
aimed to assess the activity of such a method in young, breast cancer patients undergoing adjuvant chemotherapy.
Patients and methods: Premenopausal patients received the LH-RH analog goserelin 3.6 mg every 4 weeks before
and during chemotherapy. According to two-stage optimal phase II Simon design, treatment was considered clinically
interesting if it was able to prevent menopause in 19 out of 29 patients of the study population. The resumption of
ovarian function was defined by a resumption of menstrual activity or by a follicle-stimulating hormone (FSH)
value £40 IU/l within 12 months after the last cycle of chemotherapy.
Results: Thirty patients were enrolled and 29 were evaluable. Median age was 38 years (range 29–47). All but one
patient received CEF regimen (cyclophosphamide, epirubicin, 5-fluorouracil). Resumption of menstrual activity was
observed in 21 patients (72%; 95% CI 52% to 87%) and a FSH value £40 IU/l in 24 patients (83%; 95% CI 63% to
93%). Menses resumption was observed in 16 out of 17 patients (94%) with age <40 years and in five out of
12 patients (42%) with age ‡40 years.
Conclusion: Goserelin given before and during chemotherapy may prevent premature menopause in the majority of
patients. The different success rate by age, however, indicates the need of a prospective evidence of the efficacy
of such a strategy.
Key words: breast cancer, early menopause, fertility preservation
introduction
Nearly 25% of women diagnosed with breast cancer are
premenopausal [1] and most are candidates for adjuvant
chemotherapy [2]. As a consequence of such a treatment, the
majority of these patients develop early menopause. Commonly
used chemotherapy regimens, such as CMF (cyclophosphamide,
methotrexate, fluorouracil) or CEF (cyclophosphamide,
epirubicin, 5-fluorouracil), induce menopause in nearly 60% of
patients [3]. Although cumulative dose of chemotherapy has
been associated with risk of menopause [3], different CEF
regimens seem to be associated with a similar incidence of
iatrogenic menopause. CEF regimens based on the intravenous
administration on day 1 of all drugs for six cycles
(cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2,
fluorouracil 600 mg/m2) induces menopause in 60% of patients
[4]. The dose-intensified CEF reported by Levine et al. [5]
(cyclophosphamide 75 mg/m2 orally days 1–14, epirubicin
60 mg/m2 i.v. days 1 and 8, and fluorouracil 500 mg/m2 i.v. days
1 and 8) given for six cycles was associated with a 51% rate
of menopause. The occurrence of chemotherapy-induced
menopause rises with increasing age, ranging from 22% to 61%
in women under 40 years of age and from 61% to 97% in those
over 40 [6].
Premature menopause has significant consequences, such as
hot flushes and night sweats, psychosocial problems, atrophic
vaginitis, dyspareunia, skeletal osteoporosis, cardiovascular
effects and loss of fertility. This latter effect is a major concern
for young women with breast cancer and in nearly 29% of cases
it does influence treatment decision [7]. Therefore, preservation
of ovarian function and particularly of fertility is an emerging
attempt of current clinical research.
No standard treatment to prevent chemotherapy-related
premature menopause is available so far. Current attempts
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procedures not easily available in all centers, such as
cryopreservation and reimplantation of ovarian tissue [8, 9].
Hormonal methods may offer an important strategy to reduce
the gonadotoxicity of chemotherapy. Since cytotoxic drugs
mainly affect tissues with a rapid cellular turnover, it has been
suggested that a state of induced gonadal inhibition during
exposure to chemotherapy may protect the gonads [10, 11].
Chronic administration of luteinising hormone-releasing
hormone (LH-RH) analogs decreases follicle-stimulating
hormone (FSH) secretion and suppresses gonadal function. This
approach has been suggested as a possible protective method
against gonadal damage induced by chemotherapy. There is
convincing evidence in female rats [12, 13] and rhesus monkeys
[14] that treatment with LH-RH analogs can reduce the ovarian
toxicity of chemotherapy and preliminary clinical data suggest
that this approach works in lymphoma patients [15].
The aim of this phase II study was to evaluate the activity of
goserelin, a LH-RH analog, in preventing the development of




Patients with histologically confirmed breast cancer (stages I–III) who had
undergone modified mastectomy or breast-conserving surgery plus full
ipsilateral axillary node dissection or sentinel lymph node biopsy were
eligible for enrollment in the study if they were premenopausal and
candidates for adjuvant chemotherapy. Premenopausal status was defined as
the presence of active menstrual cycles within 6 weeks before initiation of
chemotherapy. Other eligibility criteria were as follows: age ‡18 years;
no evidence of metastases or localized cancer recurrence; no prior
chemotherapy for cancer or non-neoplastic diseases; no previous or
concomitant other malignancy within the past 5 years except basal or
squamous cell carcinoma of the skin or adequately treated in situ carcinoma
of the cervix; no pregnancy or nursing.
All patients gave their written informed consent before study entry.
study design
This was a single center, prospective, single-arm, phase II study on goserelin
activity in preventing chemotherapy-induced menopause. FSH was used as
the biochemical marker of menopausal status. FSH was evaluated before
treatment and at 3, 6, 9 and 12 months after the last cycle of chemotherapy.
A FSH level above 40 IU/l indicated a post-menopausal status. Estradiol (E2)
levels were also assessed with a value below 20 pg/ml indicating a
post-menopausal status. Menstrual activity was recorded during and
after chemotherapy.
The success of the experimental treatment was defined by the resumption
of menstrual activity within 12 months after the last cycle of chemotherapy
or by the occurrence of a FSH level £40 IU/l between 3 and 12 months
after the last cycle of chemotherapy.
The Ethical Committee of the National Cancer Research Institute of
Genoa, Italy approved the protocol.
treatment regimen
Goserelin (Zoladex, supplied by AstraZeneca, Italy) 3.6 mg was administered
subcutaneously at least 1 week before the first cycle of chemotherapy and
then every 4 weeks for the duration of chemotherapy. The last
administration of goserelin was given before the last cycle of chemotherapy.
Patients with hormone receptor positive tumors received tamoxifen at the
end of chemotherapy and if a resumption of menstrual activity was observed
during the 12-month follow-up after the last cycle of chemotherapy, they
restarted goserelin and continued it for at least 2 years to induce
a therapeutic temporary ovarian suppression.
assessment of toxicity
Toxicity was evaluated on the first day of each chemotherapy cycle according
to the National Cancer Institute Common Toxicity Criteria, version 2.0.
Prespecified side-effects, which were considered related to goserelin
administration, were as follows: hot flushes, vaginal dryness, headache,
mood swings, breast changes, depression, hypotension, hypertension and
decrease of bone mineral density. Bone mineral density was measured using
QTC (quantitative computed tomography) measures of the spine.
statistical methods
A two-stage optimal phase II Simon design was used. It was assumed that an
experimental drug, in order to warrant further studies, should be associated
with a success rate of at least 80%, whereas a drug associated with
a proportion of successes £50% was of no interest. For a power of 90%
against the hypothesis of an 80% rate of success and a 5% false-positive error
rate against the hypothesis of a success rate of 50%, nine patients have to be
enrolled onto the first stage. If five or fewer successes were observed, then the
enrollment had to be terminated. If six or more successes were observed,
then an additional 20 patients had to be accrued. The drug was considered
sufficiently promising to warrant further studies if 19 or more successes were
seen among the total of 29 patients.
Exact 95% binomial confidence intervals (CIs) were computed for rates.
The median test was used to verify whether two independent groups differ in
central tendencies. To investigate the effect of FSH and E2 on time to
resumption of menstrual activity, two Cox proportional hazard models were
fit to the data. FSH (£40 IU/l versus >40 IU/l) and E2 (<20 pg/ml versus
‡20 pg/ml) values, observed during the follow-up, were treated as binary
time-dependent variables. Time to resumption of menstrual activity was
calculated from the day of the last chemotherapy administration until
menstrual resumption. Women who did not resume menstrual activity
during the follow-up period were censored at the day of their last follow-up
visit. All significance tests were performed at the 0.05 level.
results
Thirty patients were enrolled between October 2001 and June
2003. One patient refused chemotherapy after study entry and
was considered not evaluable. The main baseline characteristics
of the 29 evaluable patients are reported in Table 1. Median age
was 38 years (range 29–47 years). At study entry the median
time from last menses was 18 days (range 1–47 days). Median
baseline value of FSH was 4.64 IU/l (range 1.68–20.3) and
median baseline value of E2 was 114.5 pg/ml (range 26–339).
All but one patient received CEF (cyclophosphamide 600
mg/m2, epirubicin at doses ranging from 60 to 90 mg/m2,
5-fluorouracil 600 mg/m2) chemotherapy administered every
3 weeks for six cycles. Chemotherapy was stopped before the
total number of planned cycles in three patients due to toxicity:
after five cycles in two patients and after one cycle in one patient.
Goserelin was stopped before the completion of the planned
treatment in three patients (after two administrations in two
patients and after four administrations in one patient) due to
chemotherapy interruption (two patients) and refusal to
continue goserelin (one patient). All 25 patients (86%) with
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receptor-positive tumors received tamoxifen after
chemotherapy. Data about treatment compliance are reported
in Table 2.
goserelin-related toxicity
The majority of the patients reported side-effects possibly related
to the administration of goserelin (Table 3), although
a concurrent effect of chemotherapy on such a toxicity cannot be
ruled out. These toxicities were of grade 1–2 in all cases. Bone
mineral density was assessed at baseline, within 3 months from
start of goserelin, in 14 patients and after more than 3 months in
13 patients. Median T-scores were 1.50 (range 2, +2) at
baseline and 2.40 (range 4, 2) after more than 3 months of
goserelin treatment, indicating a decrease in bone mineral density.
activity
Among the 29 evaluable patients, one patient stopped
chemotherapy after one cycle due to severe toxicity. She
continued goserelin plus tamoxifen as antitumor treatment and
was considered a failure for the purpose of this study. The
remaining 28 patients had evaluation of ovarian function during
the planned 12-month follow-up period after the last cycle of
chemotherapy. Resumption of menstrual activity was observed
in 21 patients (72%; 95% CI 52% to 87%). Among the 25
patients in whom the FSH assessment was performed, a value
£40 IU/l was observed in 24 (83%; 95% CI 63% to 93%). Three
patients without FSH assessment experienced resumption of
menstrual activity (Table 4). According to our definition of
success (FSH £40 IU/l and/or resumption of menstrual menses),
the overall rate of success was 97% (95% CI 82% to 100%).
Median time to menstrual resumption was 5.5 months (range
2.1–12 months). With increasing age a trend to a longer median
time to menses resumption was observed: 2.7 months (range
2.4–6.4) in patients £35 years old (seven patients); 6.1 months
(range 2.1–11.5) in patients 36–38 years old (eight patients); and
7.9 months (range 2.9–12.0) in patients ‡39 years old (six
patients). Menstrual activity resumption was observed in 16 out
of 17 patients with age <40 years (94%) and in five out of
12 patients with age ‡40 years (42%) (Table 5).
Table 1. Patient characteristics at study entry
Patients (n = 29)
n %
Age
<40 years 17 59


















ER positive and/or PgR positive 25 86




Table 2. Treatment compliance
Patients (n = 29)
Chemotherapy type [no. patients (%)]
C600E60–75–90F600 28 (97%)
A60C600 · 4 cycles followed by T175 · 4 cycles 1 (3%)
Median number of chemotherapy cycles 6
Range 1–8
Median number of goserelin administration 5
Range 2–6
Interval (days) between first goserelin administration
and the start of chemotherapy
Median 7
Range 7–15




Table 3. Grade I–II goserelin-related toxicity
Toxicity Patients (n = 29)
n %
Hot flushes 28 97
Headache 26 90
Sweating 26 90
Mood modification 26 90
Vaginal dryness 17 59
Table 4. Menstrual activity resumption, FSH and E2 values
Menstrual activity resumption









FSH £40 IU/l 17 7 0 24 (83%)
FSH >40 IU/l 1 0 0 1 (3%)
FSH unknown 3 0 1a 4 (14%)
E2 <20 pg/ml 3 3 0 6 (21%)
E2 >20 pg/ml 15 4 0 19 (65%)
E2 unknown 3 0 1a 4 (14%)
aOne patient stopped chemotherapy after one cycle and was considered
as a failure.
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All 17 patients (59%) with hormone-receptor positive tumors
and resumption of menstrual activity restarted goserelin for
a planned duration of at least 2 years.
FSH and E2 assessment
Distribution of patients by menstrual activity resumption and
FSH and E2 levels is reported in Table 4.
Median values of minimum FSH level observed in each
patient between 3 and 12 months after the last cycle of
chemotherapy were significantly lower in patients who resumed
menstrual activity (6.09 IU/l, range 2.18–59.9) compared with
patients who did not (19.20 IU/l, range 9.16–32.3) (P = 0.02).
Median values of maximum E2 level observed in each patient
during the follow-up were significantly higher in patients with
menses resumption (181 pg/ml, range <20–766) than in patients
without menses resumption (23 pg/ml, range <20–514)
(P = 0.03). Cox proportional hazard models showed that a
value of FSH £40 IU/L was not predictive of future menstrual
resumption (hazard ratio 1.41, 95% CI 0.47–4.23, P = 0.53),
whilst E2 level ‡20 pg/ml was a strong predictor of menses
resumption (hazard ratio 6.17, 95% CI 2.20–17.19, P = 0.0005).
The potential impact of tamoxifen on FSH and E2 levels
was evaluated in patients with menses resumption. Minimum
FSH values were significantly lower in the 14 patients taking
tamoxifen (4.83 IU/l, range 2.18–16.10) compared with the
four patients who did not (17.6 IU/l, range 6.48–59.90)
(P = 0.02). Maximum E2 levels were higher but not
significantly different between patients assuming and not
assuming tamoxifen (201 pg/ml, range <20–766 versus
151.5 pg/ml, range <20–283) (P = 0.27).
discussion
The results of this phase II study suggest that goserelin, given
before and continuing every 4 weeks during cytotoxic
chemotherapy, may prevent iatrogenic early menopause. On the
basis of our ‘a priori’ criterion for defining the success, the
success rate was as high as 97% (95% CI 82% to 100%). Because
FSH value alone cannot be considered a reliable marker, a better
indicator of ovarian function preservation is menses
resumption, which was observed in 72% of patients
(95% CI 52% to 87%).
While the resumption of menstrual activity is a clear
marker of ovarian function, its absence does not necessarily
indicate the lack of such a function [16]. Our study suggests
that a level of E2 ‡20 pg/ml after chemotherapy indicates a
premenopausal status and that it is predictive of future
menstrual activity resumption. FSH value alone cannot be
considered a reliable marker of ovarian function. Although
median values of FSH were significantly lower in patients who
resumed menses compared with those who did not, menstrual
activity was observed in one patient despite an FSH value
>40 IU/l. In addition a low (<40 IU/l) FSH level was not
predictive of future menses resumption. The use of tamoxifen in
premenopausal women can affect both FSH and E2 secretion.
The effect of tamoxifen on FSH is unclear [17]. An increase in
FSH secretion has been seen in some studies, but in other studies
this was not found. In our study, lower FSH levels were observed
in patients taking tamoxifen. However, due to the low number
of patients, such findings should be considered with caution.
The previously reported [18] increase in E2 secretion induced
by tamoxifen was also observed in our study, although the
difference between patients on tamoxifen versus those not
taking it was not statistically significant.
Methods other than administration of LH-RH analogs are
currently under evaluation to preserve ovarian function. Among
them transplantation of cryopreserved ovarian tissue is very
promising although little clinical data on its efficacy are available
so far. Main limiting factors for this method are: the availability
of the procedure, which may be limited to selected centers; the
limited life span of ovarian grafts [9], suggesting that
transplantation may be useful for fertility restoration but not for
the purpose of long-term hormone production; and the risks
related to the invasiveness of the procedure and to the potential
for ovarian tissue to harbor malignant cells capable of inducing
a relapse on reimplantation [19]. Moreover the reported case of
live birth after orthotopic transplantation of cryopreserved
ovarian tissue [20] has been criticized as the definitive evidence
for the feasibility of pregnancy resulting from such procedures
[21]. The recently reported strategy of in vitro fertilization and
embryo cryopreservation after ovarian stimulation with FSH
and tamoxifen or letrozole is a promising approach [22] but
both its safety and efficacy are still unknown [23].
Concerns about the use of LH-RH analogs before and during
chemotherapy are the potential interaction with chemotherapy
and the potential detrimental effect on the outcome of the lack
of chemotherapy-induced menopause. Data from randomized
studies [24, 25, 26] as well as the results of the Early Breast
Cancer Trialists’ Collaborative Group meta-analysis [27] did
not show a different outcome in patients who had received
concurrent ovarian suppression and chemotherapy compared
with patients treated with chemotherapy alone and thus they did
not support the first concern. Regarding the second concern,
there is some evidence to suggest that chemotherapy-induced
menopause is associated with an improved prognosis in early
breast cancer patients [6]. Although reports are not consistent, it
cannot be ruled out that resumption of ovarian function and the
consequent estrogen production may adversely affect the
survival, at least in patients with hormone receptor positive
tumors. In our strategy, this reasonable concern was addressed
by restarting goserelin administration at the time of ovarian
function resumption. LH-RH treatment was continued for at
least 2 years, thus assuring a commonly accepted time of
therapeutic ovarian function suppression [28]. The activity of
Table 5. Menses resumption and patient age
Age (years) Total patients Menses resumption
n %
29–38 15 15 100
39 2 1 50
40 3 1 33
41 3 3 100
42 1 0 0
43 1 0 0
44 3 0 0
47 1 1 100
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goserelin in preventing early menopause in patients with
receptor positive tumors need to be confirmed after the 2-year
period of induced ovarian suppression, when resumption of
ovarian function is expected in nearly 80% of patients [27].
Our results corroborate with the findings of other studies in
breast cancer patients, showing that the activity of LH-RH
analogs in preventing early menopause ranged from 86% to
100% [29–31]. However, our study indicates a different effect
according to patient age. Menstrual activity resumption was
observed in 94% of patients younger than 40 years and in 42%
of those aged 40 or more. Using CEF regimens like that used in
our study, the expected rate of menstrual activity resumption is
nearly 40% in the overall group of premenopausal patients, 64%
in patients younger than 40 years and 30% in those aged 40 or
more. Although comparison of these figures with those of the
present study suggest an improvement in the preservation of
ovarian function by the use of goserelin, it cannot be ruled out
that age itself instead of LH-RH analog treatment is the main
determinant in ovarian function preservation. Despite LH-RH
analog treatment being claimed as an option for menopause
prevention [15], definitive evidence of its role needs to be
assessed in ongoing phase III studies.
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